The demonstration that iTRUCK19.18 can also be used to eliminate pancreatic tumor cells expressing CD19 both in vitro and in vivo opens the doors to use LOP18 to improve potency not only of other CAR-T cells directed to different tumor antigens (HER2, CEA, BCMA, etc.), but also other immunotherapies such as TILs. The gene discussed is TNFRSF17; the disease is neoplasm.